

Organisation
of European
Cancer Institutes



OECI 2015

Oncology Days

P O R T O 2 0 1 5
**GENERAL ASSEMBLY,
SCIENTIFIC CONFERENCES
AND RELATED EVENTS**

*Instituto Português de Oncologia
do Porto (IPO-Porto)*
June 22nd - 24th

 EurocanPlatform

ecancermedicalscience

Official OECI Journal

FINAL
PROGRAMME

OECD
INNOVATIVE
HIGH-QUALITY
CANCER CARE
THROUGH
COORDINATING
RESEARCH AND
EDUCATION

Welcome to the OECI Oncology Days 2015

For the third time, the Directors of the European Cancer Centres will convene in Portugal, a country which, since the OECI's foundation, has shown an extraordinary interest in our Organisation, as witnessed by the participation of all the cancer centres of the *"Instituto Português de Oncologia do Porto FG, EPE"* network in the OECI Accreditation and Designation Programme.

Each participating centre has received the OECI Certification and I hope that the Portuguese example, as in Italy, will be followed by other countries.

In this first year of my Presidency, I have been working on consolidating the OECI mandate and how our organisation can better respond to the needs of a rapidly changing society, patient needs, and those of our members. In recent years, the fast paced progress of science and technology has brought radical change to the very structure of our institutions, in order to meet the needs that personalised medicine now requires. There is an increasing need to work together to speed up the translation process, to give all our patients access to the best care and to reduce the unbearable burden of applied research that requires an increasing amount of human and financial investment.


The OECI membership should be seen as an investment that will increasingly become a two-way process in which the Institutes play a proactive and collaborative role. I am convinced that active involvement of the cancer institutes is our trump card if we want to qualify as THE European network of cancer institutions, formally recognized by the European Union. Let us not forget that the OECI is an inclusive Organisation and our wealth is represented by the diversities that exist amongst our member institutes.

The 2015 OECI Oncology Days programme sums up concisely how the process of OECI accreditation and designation, 5 years since the release of the first certification, helps to improve the organisational system, to secure the quality of our member institutes and to guarantee appropriate care to our patients, through multidisciplinary and comprehensiveness. Personalised medicine will be challenging the current status quo in many of the processes in our cancer centres. We decided, therefore, to integrate those aspects and their impacts in the scientific session.

The 2015 Oncology Days is the 37th time that the Directors of European cancer centres meet. A solid example of the efforts made by the OECI and its members in supporting the role of a European coordinator, in order to reduce fragmentation, to improve the quality of care and research and to evaluate the cost-benefits linked with the application of new therapeutics, thereby avoiding unnecessary care approaches.

We thank the local Organisers and in particular the *"Instituto Português de Oncologia do Porto FG, EPE"*, which has made this event possible.

Dominique de Valeriola
OECI President



OECI2015 ONCOLOGY DAYS

Host welcome

Dear Colleagues,

It is with enormous honor that we receive all of you in our institution and city.

The Instituto Português de Oncologia do Porto is a standalone cancer Centre strategically committed with quality care and patient safety issues. The affiliation in OECI was very important in the past and we believe that in the future it will be the forum of excellence to represent cancer deliver organization in the European Community.

The crossroads of investigation and integration in care are always present in our mind and we hope that this meeting in Porto can strengthen the OECI vision for comprehensiveness.

We wish you a fruitfull and happy journey in Porto.



A handwritten signature in black ink, appearing to read 'L. Pontes'.

Dr. **Laranja Pontes**
IPO-Porto President

Introduction to the OECI

The OECI is a non-governmental Organisation founded in Vienna, in 1979.

The primary objectives of its 70 Members are to reduce fragmentation and to give all European cancer patients the possibility of receiving the best available care. The OECI Members have established themselves in the innovation frontline by tailoring solutions to the individual patient, by gaining in efficiency and efficacy and with the potential to transform the way healthcare is delivered today.

To better achieve its goals, the Organisation works in close collaboration with the European Cancer Patients Coalition.

The OECI goals are achieved by promoting and strengthening the concept of Comprehensive Cancer Centres in Europe in order to improve quality in cancer care and translational research, as well as from an organisational viewpoint. In an effort to efficiently contribute towards an increase in the quality of care, 40% of all OECI Members are already participating in the OECI Accreditation/Designation programme.

In 2016, some of the already certified Centres will be re-visited in order to confirm their Designation status, according to the revised quality standards for comprehensive and multidisciplinary cancer care in European cancer centres, as published in the Second Edition of the OECI Accreditation and Designation User Manual. So far, 29 European wide, comprehensive and clinical cancer centres have taken part in the OECI Accreditation & Designation programme.

The OECI interacts with its members in the definition of tasks of international and common interest. The common goal is to facilitate member participation in European projects and programmes, to support training activities on forefront topics, which provides a sound basis for accelerated development of expertise and future collaborative work. This in turn attracts professionals and officers from across disciplines and ultimately underlines the value of multidisciplinary actions.

Giving the crucial role to pathology departments in oncology and in lieu of the expected “influx” of new markers and diagnostics, the OECI acts in close cooperation with the European Association for Cancer Research and the European Society of Pathology, in order to better disseminate the innovation process amongst its members and abroad. The EACR-OECI training course series in Luxembourg on “Precise Medicine”, and on “Molecular Pathology Approach to Cancer” in Amsterdam, are just two examples of the OECI efforts to promote the dissemination of innovation.

Managerial support is mainly organised through the President's Office and the Central Office in Brussels, alongside the Liaison and Director's Office in Genoa. You can find more information about the Organisation at www.oeci.eu <<http://www.oeci.eu>>. The dissemination of the OECI activities, reports, proceedings are also publicized through [ecancermedalscience](http://www.ecancer.org), the Official OECI e-Journal at <<http://www.ecancer.org>>.

OECI2015 ONCOLOGY DAYS

The OECI Board



President
Dominique de Valeriola
Brussels, Belgium



Past President
Wim H. van Harten
Amsterdam, The Netherlands



Executive Secretary
Marco A. Pierotti
Milan, Italy



Treasurer
José Maria Laranja Pontes
Porto, Portugal



Elected Member
Carlos Caldas
Cambridge, United Kingdom



Elected Member
Gunnar Sæter
Oslo, Norway



OECI Director
Claudio Lombardo
Genoa, Italy



OECI Central Office
Guy Storme
Brussels, Belgium

Working Groups and Activities



Accreditation and Designation
Mahasti Saghatchian
Paris, France



Biobanks and Molecular Pathobiology
Giorgio Stanta
Trieste, Italy



Cost - Benefit
Wim H. van Harten
Amsterdam, The Netherlands



Palliative Care
Massimo Costantini
Reggio Emilia, Italy



EurocanPlatform
Ulrik Ringborg
Stockholm, Sweden



START-OECI
Lisa Licitra
Milan, Italy



Communication and Dissemination
Gordon McVie
Milan, Italy



Claudio Lombardo
Genoa, Italy

OECI2015 ONCOLOGY DAYS

The OECI Quality Network



- ★ OECI Members A&D certified
- ★ OECI Members in the A&D process
- Other OECI Members
- ★ Non - OECI Members in the A&D process

OECD2015 ONCOLOGY DAYS

The OECD membership

Austria

- **Comprehensive Cancer Center Graz**, Graz
- **Zentrum für Tumorerkrankungen Linz Onkologisches Leitspital für Oberösterreich**, Linz
- **Comprehensive Cancer Center Vienna**, Vienna

Belgium

- ★ **Institut Jules Bordet (IJB)**, Brussels 
- ★ **Kankercentrum Brussel**, Brussels
- **Institut Roi Albert II**, Brussels

Czech Republic

- ★ **Masarykuv onkologický ústav**, Brno
- **Institut biostatistiky a analýz Lékařské a Přírodovědecké fakulty Masarykovy university**, Brno

Denmark

- **Kræftens Bekæmpelse Center for Kræftforskning**, Copenhagen

Estonia

- ★ **Tartu Ülikooli Kliinikum**, Tartu 
- **North Estonia Medical Centre**, Tallin

Finland

- ★ **HYKS Syöpäkeskus Helsinki University**, Helsinki 

France

- ★ **Gustave Roussy**, Villejuif 
- **Centre de Lutte Contre le Cancer Paul Strauss**, Strasbourg
- **Institut Curie**, Paris
- **Centre Henri Becquerel**, Rouen
- **Centre Leon Berard**, Lyon
- **Centre Alexis Vautrin**, Nancy

Germany

- ★ **Universitäts KrebsCentrum Dresden**, Dresden
- **Charité Comprehensive Cancer Centre**, Berlin
- **Deutsches Krebsforschungszentrum (DKFZ)**, Heidelberg

Hungary

- ★ **Országos Onkológiai Intézet**, Budapest

- **National Koranyi Institute of TB and Pulmonology**, Budapest

Italy

- ★ **Centro di Riferimento Oncologico, Istituto Nazionale Tumori**, Aviano 
- ★ **Istituto Europeo di Oncologia**, Milan 
- ★ **Azienda Ospedaliera Arcispedale S. Maria Nuova IRCCS**, Reggio Emilia 
- ★ **Fondazione IRCCS Istituto Nazionale dei Tumori di Milano**, Milan 
- ★ **Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico**, Bari 
- ★ **IRCCS Azienda Ospedaliera Universitaria San Martino - IST - Istituto Nazionale per la Ricerca sul Cancro**, Genova 
- ★ **Istituto Oncologico Veneto IRCCS-IOV**, Padova 
- ★ **Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale" (INT-Pascale)**, Napoli
- ★ **IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB)**, Rionero in Vulture
- ★ **Istituto Nazionale Tumori Regina Elena**, Roma
- **Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori [IRST]-IRCCS**, Meldola-Forlì
- **European School of Oncology (ESO)**, Milan
- **IFOM - FIRC Institute of Molecular Oncology**, Milan
- **Ospedale San Raffaele (OSR)**, Milan
- **Ente Ospedaliero Ospedali Galliera**, Genova
- **IRCCS - Istituto di Ricerche Farmacologiche Mario Negri**, Milan
- **Nerviano Medical Sciences Group S.r.l.**, Nerviano

Lithuania

- ★ **National Cancer Institute**, Vilnius 




Norway

- ★ **Oslo Universitetssykehus (OUS)**, Norway

Poland

- **Wielkopolskie Centrum Onkologii**, Poznan

Portugal

- ★ **Instituto Português de Oncologia de Coimbra FG, EPE**, Coimbra 
- ★ **Instituto Português de Oncologia de Lisboa FG, EPE**, Lisbon 
- ★ **Instituto Português de Oncologia o Porto FG, EPE**, Porto 

Romania

- ★ **The “Prof. Dr. Ion Chiricuta” Institute of Oncology (IOCN)**, Cluj
- **SC RTC Radiology Therapeutic Center – Amethyst Radiotherapy**, Otopeni

Russia

- **Tatarstan Cancer Center “TCC”**, Kazan
- **N.N. Blokhin Russian Cancer Research Centre**, Moscow
- **P.A. Herzen Moscow Cancer Research Institute**, Moscow

Serbia

- **Institute of Oncology (IOV) Sremska Kamenica Novi Sad**, Sremska Kamenica

Slovakia

- **Ústav experimentálnej onkológie SAV**, Bratislava

Slovenia

- **Onkološki inštitut Ljubljana**, Ljubiana

Spain

- ★ **Fundación Instituto Valenciano de Oncología IVO Foundation**, Valencia 

- **Institut Català d'Oncologia**, Barcelona
- **Instituto Madrileño de Oncología (Grupo IMO)**, Madrid

Sweden

- **Karolinska Institutet**, Stockholm

The Nederland

- ★ **Netherlands Cancer Institute**, Amsterdam 
- **Maastricht University Medical Centre**, Maastricht
- **Radboudumc Centrum voor Oncologie**, Nijmegen
- **IKNL Integraal Kankercentrum Nederland**, Utrecht
- **Erasmus MC Daniel den Hoed Cancer Centre**, Rotterdam



Turkey

- **Dokuz Eylül Üniversitesi Onkoloji Enstitüsü**, Izmir

Ukraine

- **RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (IEPOR)**, Kyiv

United Kingdom

- ★ **Cambridge Cancer Centre**, Cambridge 
- ★ **The Christie NHS Foundation Trust**, Manchester 
- ★ **King's Health Partners Integrated Cancer Centre**, London
- **Cancer Research UK Glasgow Centre**, Glasgow
- **Imperial College Healthcare NHS Trust**, London

Non-OECI Members in the A&D process

- ★ **AZGroeninge Kortrijk**, Belgium
- ★ **Vejle Cancer Hospital**, Denmark
- ★ **Anadolu Medical Centre**, Kocaeli, Turkey

OECD2015 ONCOLOGY DAYS

Instituto Português de Oncologia do Porto Francisco Gentil, EPE

DESCRIPTION OF THE INSTITUTE

The Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto) opened in April 1974, as a unit of the Public Sector and became a Corporate Public Entity with an annual service contract with the Minister of Health.

Moreover, it is the top line reference unit in oncology care in the North of Portugal, to where all the most complex cases are transferred to, with about 3.7 million of habitants to serve.

MISSION

The main mission is to render high quality, humanist and efficient oncology health care to the population. It is also part of the mission to develop research, training and teaching activities within oncology.

GENERAL ORGANIZATIONAL PRINCIPLES

1. The oncologic patient is the centre around which all care activity is build. For this reason all human and technical means available must be organized in a way as to give personalized, homogenous and holistic care.
2. Multidisciplinarity is assumed as the approach of the neoplastic disease, capable of offering an integrated and sequential treatment, in accordance with the highest scientific standards.
3. To achieve these goals, multidisciplinary units are created for each pathology, named Pathology Clinics, as the basis of the whole care structure.



QUALITY

IPO-Porto has full accreditation since 2004 and certification since 2008 – ISO 9001/2000 by CHKS (Caspé Healthcare Knowledge Systems).

It is the first Comprehensive Cancer Centre in Europe accredited by OECI (Organisation of European Cancer Institutes) since 2011, and Jacie for transplantation and cell therapy.

RESEARCH

Basic Research; Translational Research; Clinical Research; Epidemiologic Research; The Portuguese Oncology Institute - Porto Research Center (CHPOP), hosted by IPO-Porto, is recognized by the Portuguese Science Foundation as an R&D unit. IPO-Porto has a consortium with IPATIMUP, which together comprises 15 translational research groups and a Clinical Trials Unit. The IPO-Porto/IPATIMUP consortium ensures a significant critical mass of investigators that allows fulfillment of the strategic institutional vision of having research as an integral part of patient care. The long-term objective of the IPO-Porto/IPATIMUP consortium is the understanding of the pathobiological mechanisms involved in carcinogenesis and in therapy response/resistance, which ultimately will help improve cancer prevention and/or treatment.

The Clinical Research Unit, which aims to collaborate in the development of more efficient therapies of cancer by participating in multicentric, carefully designed clinical trials. The unit supports all clinical departments of IPO-Porto in their participation in investigator initiated or international clinical trials, namely those promoted by EORTC, collaborative groups, or the pharmaceutical industry.

TEACHING

The main goal of the Department of Education (EPOP) is to promote continuous education in Oncology, providing state of the art transfer of knowledge to all professionals of IPO-Porto, as well as affiliated institutions and students or professionals from partner academic or health institutions. The department provides resources and facilities (+ 2.000m²) according to the educational needs identified every year which are materialized as the institutional continuous education plan.

All issues in oncology: Under-graduate Medical Training; Post-graduate Medical Training; Training for other Health Care Professionals; Training for the community.



Cancer is one of the major health issues affecting our society and is predicted to significantly increase globally as the population ages. Cancer diseases are expected to increase in the forty countries of Europe from 3.6 million cases in 2015 to 4.3 million cases in 2035, an increase of around 20%, translating to 716,000 additional cases each year. While cancer is already considered as a major chronic disease, the number of patients living with cancer is predicted to escalate from 28 to 82 million globally for the same timeline. Trends are similar in Europe, where in 2006 cancer caused 1.7 million deaths, an equivalent of three deaths/minute. This will cause the health care system to suffer a substantial extra demand, including required surveillance and recurrent treatment of both the disease and observed complications. Europe has no clear strategy to meet the increasing cancer burden, but it has a number of resources and expertise for developing the necessary translational cancer research. Both fragmentation and lack of sustainability are among the major obstacles to research collaboration in Europe and there is an urgent need for improving cooperation between basic/preclinical and comprehensive cancer centres, institutions in which care and prevention are integrated with research and education.

In response to the above challenges, the EurocanPlatform - a unique collaboration between 28 European Cancer Institutions and Organisations - targets the whole cancer research continuum from bench to bedside (basic, early and late translational, clinical, epidemiological, implementation in care, and population-based outcomes research) in an effort to improve cancer patient outcomes and reduce mortality. To achieve its objectives, the Platform focuses on three key research areas: prevention, early detection and therapeutics while also seeking to develop long-term sustainable strategies in each area.

By strengthening the integration between the different disciplines and stakeholders, the platform with its interlinked cancer centres, common infrastructures, and collaborative projects, is in a unique position to structure translational cancer research in Europe and to speed up the translation of discoveries into applications that impact patient lives. The consortia has access to large numbers of clinical samples, infrastructures e.g. biobanks with clinical information, bioinformatics, technology platforms, new and standardized technologies, as well as clinical trial units, which are all prerequisites for successful innovation and for meeting the demands of cancer therapeutics.

The EurocanPlatform prioritizes structuring actions as well as collaborative projects that facilitate rapid advances in knowledge and their translation into better cancer care, promotes education, training and mobility of young researchers in the area translational research, and disseminates information to society at large.

Counting 7 Partners, 11 Pilot Sites and the European Cancer Patients Coalition, under the coordination of the OECE, the Bench-Can project aims to improve quality of cancer patient's treatment.

With an ageing population, the burden that cancer will impose on our society is likely to increase. Cancer has replaced cardiovascular diseases as the leading cause of premature death in 28 out of 53 European countries, becoming the leading cause of death. In this framework, and in the light of an highly affecting cost-benefit analysis, the Bench-Can project focuses on identifying how European providers can be assisted in order to improve services to the patients, reduce care provision inequalities, and raise a better quality of oncologic services.

The partnership of the project challenges two key topics:

1. ensuring an active engagement of European comprehensive cancer centres, clinical centres, cancer departments and units;
2. sustain the quality of treatments and outcomes of the operating environments for health services which have to adapt to co-morbidities of an ageing population, speed the technology development and related financial constraint, and reduce differences in health systems performances within EU countries.

The 11 Bench-Can Pilot Sites help to define:

- the description of a cancer care organisation using an agreed number of indicator sets describing the comprehensive care context;
- the modeling performance of comprehensive cancer centres or cancer departments/units at general hospitals, by several matrices (e.g. organizational objectives/intermediaries; staff/teams; intermediaries/services; services/patient outcome enablers; translational research or medicine-related data).

Detail analyses will be performed on all Pilot Sites, for instance using data envelopment techniques and, in particular, visiting the centres with a restricted group of specialists in order to define and refine a final Benchmarking Tool that focuses on operations management and best clinical practices and which will be available and applied to all interested Institutes/hospitals in Europe.

The expected Bench-Can final outcomes are:

- (i) two benchmark tools planned for use in comprehensive cancer centres & cancer departments/units at general hospitals;
- (ii) the identification of areas for improvement for quality of care & patient outcomes with advanced plans adopted by the pilot sites, at first, and by a broader audience in the coming years;
- (iii) a benchmark manual with budget impact formulae for free access so to permit betterments in the management of cancer centres;
- (iv) a roadmap for future assessments of comprehensive cancer care.

At the end of the project, we expect the Bench-Can tools to be adopted as a non-profit service available to cancer centres and services across the EU.

OECI2015 ONCOLOGY DAYS

The OECI 2015 Oncology Days

Oncology Days programme

June 22nd Morning

- **Extended Board Meeting**

June 22nd Afternoon

- **Interim Meeting Bench-Can Project**

June 22nd - 23rd

- **OECI Pathology Day: Tumour Heterogeneity and Next Generation Sequencing - Morphology and Technology**

June 22nd Afternoon Session

- **Introduction and Clonal Heterogeneity**

June 23rd Morning Session

- **Heterogeneity and Phenotypic Plasticity**
- **Pharma Round Table**

June 23rd Afternoon Session

- **Round Table: Common aspects and diversities of tumour heterogeneity**
- **Round Table: Clinical biobanks and tumour heterogeneity**

June 23rd

- **OECI Core Activities Sessions**

Morning

Session 1: Role and organisation of a European Cancer Network: debating comprehensiveness

Session 2: The pillars for certification and designation of comprehensiveness

Afternoon

Session 3: Partnership with industry

Session 4: Health Economics in Oncology: connecting theory to clinical practice in cancer centers

June 24th 8,30-13,00

- **OECI General Assembly 2015**

Social event

June 23rd Evening

- **OECI 2015 Dinner Party**

Saint John's Day (Porto traditional celebration)

Dress code - casual

(restricted to OECI members and invited participants)



Interim Challenge Workshop

The aim is to share information about project results by focusing on practical knowledge with the objectives to:

- summarize findings, what we learned so far, their implications
- discuss whether it is useful for the participants who will ideally represent the project target groups
- discuss what are their needs, whether these are met by the project,
- discuss the experiences of the participants, the issues that are bothering them.

Targeted groups

- Representatives of the participating pilot sites;
- OECEI members and Eurocan Platform partners;
- European stakeholders;
- Patient group representatives.

Programme

Chairman: *Wim van Harten*

- 14.00-14.10 **Welcome, aim of the workshop**
Wim van Harten
- 14.10-14.40 **Benchmarking in comprehensive cancer care**
Ellen Nolte
- 14.40-15.20 **Bench-Can: Developing benchmarking tools (introducing the tool)**
- 14.40-15.00 **BenchCan Qualitative tool**
Anke Wind
- 15.00-15.20 **BenchCan Quantitative tool**
Isabelle Nefkens
- 15.20-15.50 *Coffee Break*
- 15.50-16.30 **Experiences of the Pilot Sites**
- 15.50-16.10 **The CRO-Aviano experience within the benchmarking process during the Pilot Sites visit**
Paolo De Paoli
- 16.10-16.30 **The National Cancer Institute experience within the benchmarking process during the Pilot Sites visit**
Ernestas Janulionis
- 16.30-16.50 **Patient's voice in benchmarking cancer care**
Pietro Presti
- 16.50-17.20 **Identifying best practices, methodology and pilot proposal**
Anke Wind and Peter Nagy
- 17.20-17.45 **Moderated discussion with the audience**
- 17.45-18.00 **Summary of main discussion and action points and closing**

June 22nd
Instituto Português de
Oncologia do Porto
(IPO-Porto)
Room
Biblioteca / Library

This event arises from the project Bench-Can which has received funding from the European Union, in the framework of the Health Programme.



Co-funded by the Health Programme of the European Union

OECD Pathology Days

Tumour Heterogeneity and Next Generation sequencing: Morphology and Technology

June 22nd

Instituto Português de Oncologia do Porto
(IPO-Porto)

Audatório Principal
Main Auditorium

Introduction and Clonal Heterogeneity

Chairs: *Fatima Carneiro and Rui Henrique*



14.30-14.45 **Introduction**

14.45-15.15 **Why study tumour heterogeneity from a practical point of view in diagnostic and clinical research?**

Giorgio Stanta



15.15-16.00 **Can heterogeneity affect predictive biomarker diagnosis?**

Marco Gerlinger



16.00-16.30 **How can heterogeneity modify cancer diagnostics?**

Manfred Dietel



16.30-17.00 *Coffee Break*

17.00-17.30 **Colorectal cancer molecular subtypes: from patients to preclinical models and back. The problem of heterogeneity**

Enzo Medico

17.30-18.00 **NGS, clonal heterogeneity and cancer diagnostics**

Gerald Hoefler

18.00-18.30 **Can heterogeneity be studied in liquid biopsies?**

Vera Klotten

OECI Pathology Days

Tumour Heterogeneity and Next Generation sequencing Morphology and Technology

June 23rd
Instituto Português de
Oncologia do Porto
(IPO-Porto)
Auditório Principal
Main Auditorium

Phenotypic Heterogeneity

Chairs: *Manfred Dietel* and *Gerald Hoefler*

09.00-09.20 **Morphological and immunohistochemical heterogeneity in soft tissue neoplasia: diagnostic challenges**

Mariana Afonso

09.20-09.40 **Molecular heterogeneity of prostate carcinomas**

Manuel Teixeira

09.40-10.00 **Can phenotypic heterogeneity be fuelled by exosomes?**

Sónia Melo

10.00-10.20 **Molecular heterogeneity in premalignant lesions: is it clinically relevant?**

José Carlos Machado

10.20-10.50 *Coffee Break*

Round Table

10.50-13.00 **Industry, the point of view on Heterogeneity**

Chairs: *David Henderson* and *Kurt Zatloukal*

Participants: *David Henderson*

Heterogeneity and treatment efficacy

Guido Henning

Standardized DNA and RNA extraction from FFPE Tumor tissue and impact of TCC (tissue heterogeneity) on expression profiling

Hannes Arnold

Resolving tumor heterogeneity in solid FFPE samples by DEPArray digital sorting

Pasquale De Blasio

TMA as tumour heterogeneity study instrument

13.00-14.00 *Lunch*



OECD Pathology Days Tumour Heterogeneity and Next Generation sequencing Morphology and Technology

June 23rd

Instituto Português de
Oncologia do Porto
(IPO-Porto)

Audatório Principal
Main Auditorium

Phenotypic Heterogeneity



14.00-16.00 **Round Table**
**Common aspects and diversities
of Tumour Heterogeneity, is a standardization
possible?**

Chairs: Fred Bosman and Giorgio Stanta

Participants: **Anna Sapino**
Breast
Cord Langner
Gastroenteric Tract
Lina Carvalho
Lung
Arndt Hartmann
Uro-pathology
Maria Rosaria Raspollini
Gynecological pathology
Isabel Fonseca
Head and neck



16.00-16.30 *Coffee Break*

16.30-18.30 **Round Table**
Clinical Biobanks, how to tackle Heterogeneity
Chairs: Jan-Eric Litton and Marialuisa Lavitrano

Participants: **Peter Riegman**
Heterogeneity in clinical research
Kurt Zatloukal
**Sampling strategy and quality requirements to address tumor
heterogeneity in biobanking**
Caroline Heckman
**Heterogeneity in hematological disease: Challenges and
solutions for NGS-based analyses**
Ulf Landegren
Tumour heterogeneity studied at the protein level
Stefan Willems
Heterogeneity in molecular data reporting: how to get rid of that

General Session OECEI core activities

June 23rd
Instituto Português de
Oncologia do Porto
(IPO-Porto)
Auditório Azul
Blue Auditorium

Morning Session Part 1

Role and organisation of a European Cancer Network: debating comprehensiveness

Chairs: Dominique de Valeriola

Welcome: the OECEI vision of comprehensiveness in networks

Dominique de Valeriola

The European Quality Network and the Reference Network for Rare Cancers

Gemma Gatta

Cancer Core Europe: a platform to start meaningful European co-operation

Carlos Caldas

Organisation of cancer research and care at the P.A. Herzen Federal Cancer Centre, and collaborations with other centres

Andrey Kaprin

The expectation of patient's association about CCNetwork

Francesco De Lorenzo

Discussion

Morning Session Part 2

The pillars for certification and designation of comprehensiveness

Chairs: José Laranja Pontes

Revised OECEI standards for certification and designation

Mahasti Saghatchian

The OECEI re-accreditation procedure

Femke Boomsma

The role of the A&D Auditors

Paolo De Paoli

The experience of an OECEI Member certified as Comprehensive Cancer Centre

Petri Bono

The experience of an OECEI Member certified as Clinical Cancer Centre

Ernestas Janulionis

How to improve the process: suggestions from the audience

Open Floor

OECl2015 ONCOLOGY DAYS

General Session OECl core activities

June 23rd

Instituto Português de
Oncologia do Porto
(IPO-Porto)

Auditório Azul
Blue Auditorium

Afternoon Session Part 1

Partnership with industry

Chairs: Gunnar Sæter

The changing face of drug development and role of Comprehensive Cancer Centres

Gunnar Sæter

Benchmarking comprehensive cancer care: potential role in partnership with industry

Wim van Harten

Collaboration with industry: The experience of AACI

George Weiner

Relationship with a pharma research company: a challenge for the Academia

Marco Pierotti

Discussion

Afternoon Session Part 2

Health Economics in Oncology: connecting theory to clinical practice in cancer centers

Chairs: Wim van Harten

Case Report on health economic analysis in a cancer centre

Guy Storme

Clinical and Business Impact of Integrated practice units in Porto

Francisco Rocha- Goncalves

Business impact of return to work interventions for Cancer survivors and financial impact in seven EU countries

Janne Mewes

HTarget model, a health economics approach to evaluate targeted treatment over different tumor types

Valesca Retel

Discussion

Closing

08.00 Registration

08.15 **General Assembly Constitution, welcome and approval of the Agenda**

Chairperson: *Dominique de Valeriola*

08.30 **Session 1: Administrative and financial matters**

Chairperson: *Dominique de Valeriola*

Point 1: Approval of May 2014 General Assembly's Minutes

(vote requested - decision taken at the simple majority of the OECI Full Members present or represented)

Dominique de Valeriola

Point 2: Approval of the Financial Statement 2014

(vote requested - decision taken at simple majority of the OECI Full Members present or represented)

Marco Pierotti

Point 3: 2015 and 2016 Provisional Budget

(only for 2015 budget the vote is requested – decision taken at simple majority of the OECI Full Members present or represented)

José Laranja Pontes

Point 4: OECI Board composition 2014-2017 update

(vote non requested)

Dominique de Valeriola

Point 5: Working Groups and Co-opted Board Members update

(vote not requested)

Dominique de Valeriola

Point 6: Modification of Art. 6.4 of the OECI Statute and of the Art. 3.2 of the OECI Internal Regulation: Payment and Collection of the Membership Fees

(vote requested – decision taken at the simple majority of the OECI Full Members present or represented)

Dominique de Valeriola

Point 7: OECI Membership – Annexes to Point 7

Claudio Lombardo

7.1 New applications for membership

(vote requested for full membership, decision taken at unanimity of the OECI Full Members present or represented; for associated membership, by simple majority of the OECI Full Members present or represented)

7.2 Request of transition of two Members

(vote requested - decision taken at simple majority of the votes of the OECI full members present or represented)

- 7.3 Requests of 2 Members to be dismissed from the OECI membership**
(vote not requested)
- 7.4 Proposal for discontinuing from the membership of OECI Members**
(vote requested - decision taken at two-thirds majority of the OECI Full Members present or represented)
- 7.5 Request of an Associate Member to be exempted from the payment of the OECI 2015 membership fee**
(vote requested - simple majority)

Ceremony for the delivery of the OECI Accreditation Certificates 2015

Dominique de Valeriola and Mahasti Saghatchian

Tartu University Hospital - Tartu, Estonia
Istituto Tumori Giovanni Paolo II, IRCCS – Bari, Italy
Azienda Ospedaliera – Arcispedale Santa Maria Nuova IRCCS - Reggio Emilia, Italy
Centro di Riferimento Oncologico – Istituto Nazionale Tumori - Aviano, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Azienda Ospedaliera Universitaria S. Martino-IST - Genoa, Italy
Istituto Oncologico Veneto – Padova, Italy

10.30 Coffee break

Session 2: The OECI Strategy and Working Groups Activities

Chairperson: Dominique de Valeriola

Point 8: OECI future strategies

Dominique de Valeriola

- 8.1 Accreditation & Designation** *Mahasti Saghatchian*
- 8.2 Biobanks and Molecular Pathobiology** *Giorgio Stanta*
- 8.3 BenchCan Project** *Wim H. van Harten*
- 8.4 EurocanPlatform NoE – update** *Ulrik Ringborg*
- 8.5 Palliative Care** *Massimo Costantini*
- 8.6 Communication and dissemination** *Gordon Mc Vie*

Point 9: Venues of the General Assemblies for the coming years and closure of the G.A.

Dominique de Valeriola

13.00 Lunch

Chairpersons and invited speakers

Mariana Afonso

Institute of Molecular Pathology and Immunology (IPATIMUP),
University of Porto, Portugal

Hannes Arnold

Silicon Biosystems, Italy

Petri Bono

Central Hospital Comprehensive Cancer Center, Finland

Femke Boomsma

IKNL - Netherland Comprehensive Cancer Organisation, The
Netherlands

Fred Bosman

University of Lausanne, Switzerland

Carlos Caldas

Cambridge Cancer Center, United Kingdom

Fatima Carneiro

Institute of Molecular Pathology and Immunology (IPATIMUP),
University of Porto, Portugal

Lina Carvalho

University of Coimbra, Portugal

Massimo Costantini

Azienda Ospedaliera Santa Maria Nuova IRCCS, Italy

Pasquale De Blasio

Isenet, Milano, Italy

Francesco De Lorenzo

European Cancer Patient Coalition, Brussels, Belgium

Paolo De Paoli

CRO Aviano, National Cancer Institute, Italy

Dominique de Valeriola

Jules Bordet Institute, Brussels, Belgium

Manfred Dietel

Charité Comprehensive Cancer Center Berlin, Germany

Isabel Fonseca

University of Lisbon, Portugal

Gemma Gatta

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy

Marco Gerlinger

Institute of Cancer Research, London, United Kingdom

Ivo Gut

Centro Nacional de Analisis Genomico (CNAG), Barcelona,
Spain

Wim H. van Harten

Netherlands Cancer Institute, Amsterdam, The Netherlands

Arndt Hartmann

University Erlangen-Nürnberg, Erlangen, Germany

Caroline Heckman

University of Helsinki, Finland

David Henderson

Bayer HealthCare, Berlin, Germany

Guido Hennig

Siemens Healthcare Diagnostics Holding GmbH, Eschborn,
Germany

Rui Henrique

Portuguese Oncology Institute Porto, Portugal

Gerald Hoefler

Medical University of Graz, Austria

Andrey Kaprin

P.A. Herzen Moscow Cancer Research Institute, Russian
Federation

Vera Kloten

Hospital of the RWTH Aachen University, Germany

Ulf Landegren

University of Uppsala, Sweden

Cord Langner

Medical University of Graz, Austria

Marialuisa Lavitrano

Bicocca University, Milan, Italy

Jan-Eric Litton

Karolinska Institutet, Stockholm, Sweden

Claudio Lombardo

OECD, Belgium

José Carlos Machado

Institute of Molecular Pathology and Immunology (IPATIMUP),
University of Porto, Portugal

Gordon McVie

Istituto Europeo di Oncologia, Italy

Enzo Medico

Istituto per la Ricerca e la Cura del Cancro di Candiolo, Italy

Sonia Melo

Institute of Molecular Pathology and Immunology (IPATIMUP),
University of Porto, Portugal

Janne Mewes

University of Twente, The Netherlands

Peter Nagy

National Institute of Oncology, Budapest, Hungary

Isabelle Nefkens

Panacea, Enschede, The Netherlands

Elen Nolte

European Observatory on Health Systems and Policies

Uwe Oelmüller

Qiagen GmbH, Germany

Marco A. Pierotti

FIRC Institute of Molecular Oncology (IFOM), Italy

José Laranja Pontes

Portuguese Oncology Institute Porto, Portugal

Pietro Presti

European Cancer Patient Coalition, Brussels, Belgium

Maria Rosaria Raspollini

University of Florence, Italy

Valesca Retel

Netherlands Cancer Institute, Amsterdam, The Netherlands

Peter Riegman

Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Ulrik Ringborg

Karolinska Institutet, Stockholm, Sweden

Francisco Rocha-Goncalves

Portuguese Oncology Institute Porto, Portugal

Gunnar Sæter

Oslo University Hospital, Norway

Mahasti Saghathian

Gustave Roussy, France

Ernestas Janulionis

Institute of Oncology, Vilnius University, Lithuania

Anna Sapino

University of Turin, Italy

Giorgio Stanta

Department of Medical Sciences, University of Trieste, Italy

Guy Storme

Brussels Cancer Centre, Belgium

Manuel Teixeira

Portuguese Oncology Institute Porto, Portugal

George Weiner

Holden Comprehensive Cancer Center, University
of Iowa, USA

Stefan Willems

University of Utrecht, The Netherlands

Anke Wind

Netherlands Cancer Institute, Amsterdam, The Netherlands

Kurt Zatloukal

Medical University of Graz, Austria

General timetable

	22 June 2015	23 June 2015	24 June 2015
MORNING	<p>Extended Board meeting</p> <p>Instituto Português de Oncologia do Porto (IPO-Porto)</p>	<p>OECI Pathology Day</p> <p>Tumour Heterogeneity and Next Generation sequencing Morphology and Technology</p> <p>Heterogeneity and Phenotypic Plasticity</p> <p>Pharma Round Table</p> <p>Room - Auditório Principal / Main Auditorium</p> <p>OECI Core Activities Sessions</p> <p>Session 1: Role and organisation of a European Cancer Network - debating comprehensiveness</p> <p>Session 2: The pillars for certification and designation of comprehensiveness</p> <p>Room - Auditório Azul / Blue Auditorium</p>	<p>OECI 2014 General Assembly</p> <p>Room - Auditório Principal / Main Auditorium</p>
	Lunch	Lunch	Lunch
AFTERNOON	<p>OECI Pathology Day</p> <p>Tumour Heterogeneity and Next Generation sequencing Morphology and Technology</p> <p>Introduction and Clonal Heterogeneity</p> <p>Room - Auditório Principal / Main Auditorium</p> <p>Interim Meeting Bench-Can Project</p> <p>Room - Biblioteca / Library</p>	<p>OECI Pathology Day</p> <p>Tumour Heterogeneity and Next Generation sequencing Morphology and Technology</p> <p>Round Table: Tumour heterogeneity - common aspects and diversities</p> <p>Round Table: Tumour heterogeneity - clinical biobanks</p> <p>Room - Auditório Principal / Main Auditorium</p> <p>OECI Core Activities Sessions</p> <p>Session 3: Partnership with industry</p> <p>Session 4: Health Economics</p> <p>Room - Auditório Azul / Blue Auditorium</p>	<p>Departure of the Delegates</p> <p>Sightseeing tour (see programme)</p>
EVENING	Social Dinner	Dinner Party	

OECI2015 ONCOLOGY DAYS

Social events

June 22nd
20.00 hrs.

**BenchCan, Pathology
Day and Board Dinner**
**Bern Arranjadinho
Restaurant**



June 23rd

Dinner Party
20.00 hrs.
OPO Restaurant
(Restricted to OECI Members
and invited people registration
required)



OECD
INNOVATIVE
HIGH-QUALITY
CANCER CARE
THROUGH
COORDINATING
RESEARCH AND
EDUCATION

*The Oncology Days are organised
in collaboration with:*



*The Oncology Days are
co-financed by the European
Commission through:*

*EurocanPlatform NoE
"Health-F2-2010-260791"*

*BenchCan Project
"Grant. Agreement 2012 12 11"*

THE OEI 2015 SCIENTIFIC COMMITTEE

President: Dominique de Valeriola
Members: José Laranja Pontes, Carlos Caldas,
Wim van Harten, Marco A. Pierotti, Peter Riegman,
Ulrik Ringborg, Gunnar Sæter, Mahasti Saghatchian,
Giorgio Stanta

THE OEI 2015 LOCAL SCIENTIFIC COMMITTEE

President: José Laranja Pontes
Members: Rosa Begonha, Maria Isabel Dias Sequeira,
Francisco Nuno Rocha Gonçalves,
Ilídio José Nunes de Oliveira Cadilhe

THE OEI 2015 LOCAL ORGANISING COMMITTEE

Mediana - Global Communication
Ph: +351 225 573 760
Email: geral@mediana.pt

THE OEI 2015 ONCOLOGY DAYS SECRETARIATS

BRUSSELS: Maria Cummins
GENOA: Germana Gianquinto, Giorgia Pesce, Patrizia Sommella
TRIESTE: Valentina Melita

OEI 2015 ONCOLOGY DAYS COORDINATING OFFICE

Claudio Lombardo - OEI Director
Tel: +32 2 512 01 46
Email: oeci@oeci.eu
www.oeci.eu

ecancermedicalscience
Official OEI Journal